People with diabetes who were taking GLP-1 receptor agonist drugs such as tirzepatide and semaglutide had significantly lower rates of hospital readmission, wound re-opening and hematoma after surgery ...

Ozempic has become a popular treatment for type 2 diabetes and weight loss. Discover how it works, its benefits, and ...

Novo Nordisk, the pharmaceutical company that makes Ozempic and Wegovy, stands behind the safety and efficacy of all its GLP-1 medicines when they’re used as indicated and taken under the care ...

Patients with type 2 diabetes who use semaglutide have more than double the risk of severe optic nerve damage than those who don’t use the drug. In Grauslund’s study, researchers examined a ...

I just dissolve the semaglutide under my tongue while I work out, and by the end of my workout, I can take my thyroid meds. Her objection is primarily that compounded semaglutide isn't controlled ...

Nausea is the most common side effect of semaglutide, the weight loss and diabetes medication often sold under the brand names Ozempic and Wegovy. It is particularly common after starting the ...

She then realized “how uneven his face looked” and pushed him to go to the doctors – where he was later diagnosed with tongue cancer. Stuart Kingston was diagnosed with tongue cancer after ...

GLP-1 agonists have taken the pharma world by storm, and Novo Nordisk has been at the forefront of it all thanks to blockbuster drug semaglutide, which it sells as Ozempic, Wegovy and Rybelsus.

In case you missed it, Our ‘Under The Tongue’ adidas Predator documentary dropped this week, and we also produced a beautiful compendium book alongside it, which you can now get in digital form. For ...

Semaglutide has been approved by the Food and Drug Administration (FDA) for type 2 diabetes management, weight loss, and heart disease prevention. About 137 million Americans—more than half of all ...

The firm’s oral macrocyclic peptides preserved lean muscle mass in mice given the weight-loss drug semaglutide. The company is now looking for a path to bring the peptides into the clinic ...

This year, semaglutide (Wegovy) was also approved for preventing the risk of cardiovascular events in patients with established cardiovascular disease and either obesity or overweight. Furthermore, ...